Turning Point Brands, Inc. (TPB)
NYSEConsumer StaplesTobaccoSnapshot 2026-09-04
NYSEConsumer StaplesTobaccoSnapshot 2026-09-04
Research Workspace
Put TPB beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Consumer Staples is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 20% over the past year.
View GrowthManagement screens strong on earnings delivery.
View ManagementExpectations look high — the market is pricing in about 34% growth a year, above the roughly 19% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 51% in its worst 12-month stretch.
View RiskTPB's growth depends on expanding its Modern Oral nicotine market share. Revenue grew 22% year over year, and the last quarter beat expectations with a significant earnings surprise. TPB trades at 25× P/E versus a peer median of 17×, indicating that the market is pricing in more growth than forecasted. The risk lies in the potential for a guidance cut, with a 30% probability of a miss next quarter. Peer multiples imply a price about 34% below where it trades. Our read remains intact.
Trailing returns as of 2026-09-04. TPB is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 6 analysts currently covering TPB (as of Sep 2026).
Based on 3 Wall Street analysts offering 12-month price targets for TPB in the last 4 months.
Continue this research
Compare TPB with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| TPB Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Tobacco — fair value, gap to price, and forward P/E.
Compare the value case
Put TPB next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Grow Modern Oral sales and expand market share
Aligns with growth objective for Modern Oral market share.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $75.22
The last 12 months of price, then the range of analyst 12-month targets from today’s $75.22.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Advances: Grow Modern Oral sales and expand market share
Modern oral push aligns with growth and market share objectives.

Advances: Increase Modern Oral sales guidance
Growing nicotine pouch opportunity aligns with Modern Oral sales growth.